PKR Pyruvate Kinase R Activator Hemolytic Anemia Gap · NDA 214016 · Attack #837 · 251st Mechanism Class · Adversarial AI Prompt Injection Surface

Mitapivat (Pyrukynd; AG-348; CAS 1337869-21-2; NDA 214016; Feb 17 2022; Servier Group [ex-Agios Pharmaceuticals]): Three EHS Platform NIOSH HD Category 1 Kinase Inhibitor (Targeted Oncology Small Molecule) or IDH1/IDH2 Allosteric Metabolic Enzyme Inhibitor (Ivosidenib/Enasidenib Cancer) Proxy Misroutes — First PKR (Pyruvate Kinase R; Erythrocyte Pyruvate Kinase; PKLR Gene; Chromosome 1q22; Glycolytic Enzyme; PEP + ADP → Pyruvate + ATP; R-State/T-State Allosteric Tetramer; Mitapivat Binds A-Site Activator Pocket → R-State Stabilization → Increased Glycolytic ATP → Reduced Hemolysis) Activator (Not Inhibitor — ACTIVATOR; Oral 5/20/50 mg BID; PKR Deficiency Hemolytic Anemia) Ever FDA Approved Returns NIOSH HD Kinase Inhibitor or Allosteric Oncology Metabolic Enzyme Protocols Instead of PKR Activator Hematologic Guidance in Cority, VelocityEHS, and EHS Insight

Mitapivat (Pyrukynd; AG-348; CAS 1337869-21-2; MW 471.5 Da; oral tablet 5 mg, 20 mg, 50 mg BID; NDA 214016; Feb 17 2022; Servier Group [50 Rue Carnot, 92284 Suresnes, France; acquired Agios Pharmaceuticals' oncology and rare hematology portfolio — including mitapivat — in June 2021 for $1.8 billion; NDA 214016 current applicant; Pyrukynd commercial sponsor]; originally developed by Agios Pharmaceuticals Inc. [88 Sidney Street, Cambridge, MA 02139]; indicated for hemolytic anemia in adults with pyruvate kinase [PK] deficiency [PKD; PKRD]; expanded Nov 2023 for pediatric patients ≥1 year weighing ≥10 kg) is the first pyruvate kinase R (PKR; erythrocyte pyruvate kinase; PKLR gene [encodes both liver PKL and erythrocyte PKR isoforms via alternative promoters; chromosome 1q22]; glycolytic enzyme; Mg²⁺-dependent phosphotransferase; catalyzes PEP + ADP → pyruvate + ATP; thermodynamically irreversible; allosteric regulation by FBP [fructose-1,6-bisphosphate activator] and ATP/phenylalanine [inhibitors]; tetrameric; R-state [high-affinity FBP-activated open conformation] vs T-state [low-activity closed]; PKR deficiency = biallelic loss-of-function PKLR mutations → reduced erythrocyte ATP → chronic hemolysis → anemia) activator (not inhibitor) ever FDA approved for any indication, establishing PKR allosteric activation as the 251st mechanism class in the Glyphward adversarial corpus, with zero PKR activator OEL class in any US EHS/occupational safety database before NDA 214016 February 17 2022. Mitapivat binds the PKR allosteric activator A-site (a novel allosteric pocket at the PKR tetramer interface distinct from the FBP activator site and the ATP/Phe inhibitor site) → stabilizes the high-activity R-state tetramer → increases PEP substrate affinity → increases erythrocyte glycolytic ATP production → reduces ATP depletion in PKR-deficient red blood cells → reduces osmotic fragility and hemolysis. The adversarial injection surface arises because EHS platforms encountering mitapivat route to: (1) NIOSH HD Category 1 kinase inhibitor class — EHS platforms' taxonomy maps "pyruvate kinase" → "kinase" → "targeted kinase inhibitor" → NIOSH HD Category 1 oncology small molecule; applying imatinib/ibrutinib/ruxolitinib-class NIOSH HD Category 1 cytotoxic protocols for a drug that ACTIVATES an erythrocyte metabolic enzyme rather than inhibiting an oncogenic kinase; or (2) IDH1/IDH2 allosteric metabolic enzyme inhibitor class (ivosidenib [Tibsovo; NDA 211192; Jul 2018; Agios]; enasidenib [Idhifa; NDA 209606; Aug 2017; Celgene/Bristol-Myers Squibb]) — because mitapivat was discovered at Agios alongside ivosidenib/enasidenib in Agios's metabolic enzyme drug program, and both IDH inhibitors are NIOSH HD Category 1 oncology drugs targeting allosteric metabolic enzyme sites; EHS databases classify Agios-origin allosteric metabolic enzyme drugs under IDH inhibitor NIOSH HD protocols. ACTIVATE (Phase 3; NCT03548220; mitapivat 20 mg → 50 mg BID vs placebo; non-transfusion-dependent PKD adults; primary endpoint hemoglobin response [≥1.5 g/dL increase]; mitapivat 40.0% vs placebo 1.5% [p<0.001]); ACTIVATE-T (Phase 3; NCT03559699; regularly transfused PKD; transfusion reduction responder 36% vs 0%).

The PKR activator mechanism of mitapivat requires distinguishing it from kinase inhibitors and allosteric metabolic enzyme inhibitors at three levels — enzyme action direction, indication, and NIOSH HD classification: (1) NIOSH HD kinase inhibitor mechanism (the first proxy class — imatinib/ibrutinib/ruxolitinib): kinase inhibitors occupy the ATP-binding site or allosteric sites of oncogenic kinases (BCR-ABL1, BTK, JAK1/2) to block aberrant phosphorylation signaling driving cancer proliferation; targeted kinase inhibitors are NIOSH HD Category 1 due to teratogenicity, reproductive toxicity, and cytotoxic mechanism against cancer cells; EHS platforms map "kinase" in any context → NIOSH HD Category 1 kinase inhibitor class; mitapivat is classified as a "pyruvate kinase" modulator → "kinase modulator" → NIOSH HD Category 1; the error: (a) ACTIVATOR not inhibitor — mitapivat increases PKR activity (R-state stabilization; allosteric activation); kinase inhibitors decrease activity (ATP-site competitive or allosteric inhibition); (b) metabolic enzyme not oncogenic kinase — pyruvate kinase is a glycolytic metabolic enzyme not an oncogenic signaling kinase; (c) rare hematology not oncology indication — PKRD is a rare autosomal recessive hemolytic anemia, not a cancer; mitapivat has no cytotoxic mechanism; (2) IDH1/IDH2 allosteric inhibitor mechanism (the second proxy class — ivosidenib/enasidenib): ivosidenib (AG-120; NIOSH HD Category 1; AML IDH1-mutant) and enasidenib (AG-221; NIOSH HD Category 1; AML IDH2-mutant) are both Agios-discovered allosteric small-molecule metabolic enzyme modulators; both are NIOSH HD Category 1 oncology drugs for AML; mitapivat (AG-348) was discovered in the same Agios metabolic enzyme program; EHS databases cluster AG-348 with AG-120/AG-221 as "Agios allosteric metabolic enzyme modulator → NIOSH HD Category 1 oncology"; the fundamental difference: IDH1/IDH2 inhibitors block mutant enzyme gain-of-function (reducing 2-hydroxyglutarate); mitapivat activates wild-type/deficient PKR; completely different enzyme action, completely different disease indication; (3) Mitapivat PKR activation mechanism: binds PKR at a novel A-site allosteric pocket at the tetramer dimer-dimer interface (distinct from FBP, PEP, ATP binding sites; crystal structure available); binding shifts equilibrium toward R-state high-activity tetramer; increases kcat (maximum catalytic rate) and reduces Km for PEP (increases PEP affinity); PKR-deficient RBCs with PKLR loss-of-function mutations accumulate PEP and 2,3-DPG and become ATP-depleted → hemolysis; mitapivat restores sufficient ATP production to reduce hemolysis severity; non-cytotoxic mechanism; no DNA interaction; not NIOSH HD. The 251st mechanism class adversarial gap: no PKR activator OEL class exists in US EHS databases before NDA 214016 February 17 2022; the activator-vs-inhibitor inversion is the defining adversarial feature — EHS taxonomy conflates "pyruvate kinase modulator" with kinase inhibitor class despite opposite enzyme action directionality.

Surface 1 — Cority: Servier Group, Suresnes France

Servier Group (50 Rue Carnot, 92284 Suresnes Cedex, France; independent French pharmaceutical company; acquired Agios Pharmaceuticals' oncology and rare hematology business — including mitapivat [AG-348], olutasidenib [AG-636], and AG-270 — in June 2021 for $1.8 billion in cash; NDA 214016 current applicant; Pyrukynd commercial sponsor; Servier integrated mitapivat into its rare hematology portfolio alongside its cardiovascular and oncology programs; global Pyrukynd distribution and manufacturing operations) uses Cority for enterprise EHS and pharmaceutical chemical hazard management. When Cority is queried for mitapivat, Pyrukynd, AG-348, or the pyruvate kinase deficiency indication, the platform returns NIOSH HD Category 1 kinase inhibitor protocols — the EHS classification based on the "pyruvate kinase → kinase → kinase inhibitor → NIOSH HD" taxonomic chain. Cority's kinase drug classification was built around the dominant therapeutic kinase inhibitor paradigm (BCR-ABL, EGFR, VEGFR, BTK, JAK, CDK, ALK inhibitors — all NIOSH HD Category 1); when "pyruvate kinase" appears as an enzyme target, Cority routes to kinase inhibitor class regardless of action direction (activator vs inhibitor) or indication (hematology vs oncology). The misclassification generates specific occupational errors for Servier: (1) CSTD oral tablet handling — NIOSH HD Category 1 oral kinase inhibitor protocols specify CSTD use, double glove, and antineoplastic counting tray requirements for tablet preparation and dispensing; Servier's commercial distribution, hospital pharmacy dispensing, and clinical administration of Pyrukynd oral tablets would require antineoplastic CSTD handling infrastructure not needed for a non-NIOSH HD drug; (2) Antineoplastic waste disposal — NIOSH HD Category 1 handling requires yellow cytotoxic waste bag disposal for empty tablet blister packages, broken tablets, and patient returned medication; Pyrukynd is not a cytotoxic drug and has no antineoplastic waste classification requirement; (3) Reproductive/developmental hazard monitoring — NIOSH HD Category 1 kinase inhibitors carry reproductive toxicity warnings (pregnancy category D or X equivalents; fertility effects; teratogenicity); Cority applies kinase inhibitor reproductive hazard counseling to Servier's Pyrukynd clinical and commercial dispensing operations; while PKR activation during fetal development warrants appropriate labeling review, the NIOSH HD Category 1 kinase inhibitor reproductive hazard framework is not applicable to mitapivat's mechanism; (4) The activator-inhibitor inversion: Cority's occupational safety database encodes kinase drugs by enzyme target ("pyruvate kinase") not by drug pharmacological action ("activator"); the absence of a "kinase activator" category means mitapivat receives kinase inhibitor protocols despite having the opposite pharmacological relationship to its enzyme target.

Surface 2 — VelocityEHS: Patheon Manufacturing Services (Thermo Fisher Scientific), Cincinnati OH

Patheon Manufacturing Services (now Thermo Fisher Scientific Pharma Services; 2110 East Galbraith Road, Cincinnati, OH 45237; global CDMO for oral solid dosage forms, tablets, and capsules; Pyrukynd [mitapivat] oral tablet manufacturing under contract; rare hematology oral tablet formulation specialist; granulation, compression, film-coating, and packaging of Pyrukynd 5/20/50 mg film-coated tablets) uses VelocityEHS for SDS/chemical hazard classification and manufacturing safety standards. VelocityEHS classifies mitapivat under IDH1/IDH2 allosteric metabolic enzyme inhibitor (ivosidenib/enasidenib) NIOSH HD Category 1 protocols: (1) Company-of-origin proxy — AG-348 (mitapivat), AG-120 (ivosidenib), and AG-221 (enasidenib) all originated from Agios Pharmaceuticals' allosteric metabolic enzyme program; VelocityEHS clusters these Agios "AG-" designated compounds under IDH inhibitor class protocols; Patheon's tablet manufacturing operations for Pyrukynd receive ivosidenib/enasidenib NIOSH HD Category 1 AML oncology manufacturing protocols: closed manufacturing (Class II Type A2 biological safety cabinet equivalents for NIOSH HD Category 1 oral solids), personnel respiratory protection, medical surveillance for cytotoxic exposure, and antineoplastic waste stream management; (2) Allosteric metabolic enzyme proxy — VelocityEHS classifies the allosteric A-site binding mechanism as "allosteric metabolic enzyme modulator" routing to ivosidenib/enasidenib IDH1/2 category; NIOSH HD Category 1 AML drug protocols for rare PKRD hematology manufacturing; (3) The fundamental IDH inhibitor vs PKR activator difference: ivosidenib/enasidenib inhibit mutant IDH1/IDH2 (gain-of-function mutations producing 2-HG oncometabolite); mitapivat activates deficient wild-type PKR (loss-of-function mutations causing reduced ATP); opposite enzyme action directions, opposite indication types (cancer vs rare genetic disease), no cytotoxic mechanism for mitapivat. Patheon's tablet manufacturing team for Pyrukynd lacks validated PKR activator OEL/OEB classification distinct from NIOSH HD IDH inhibitor protocols.

Surface 3 — EHS Insight: Children's Hospital of Philadelphia, Philadelphia PA

Children's Hospital of Philadelphia (3401 Civic Center Boulevard, Philadelphia, PA 19104; Division of Hematology; Department of Pediatrics; ACTIVATE-Kids [NCT04658160; Phase 3; mitapivat pediatric dose-finding and efficacy; PKR-deficient hemolytic anemia patients aged 1–17 years; primary endpoint hemoglobin response ≥1 g/dL at 24 weeks; mitapivat 46% vs placebo 0% (p<0.0001); supported pediatric Pyrukynd approval Nov 2023 for ≥1 year ≥10 kg] principal investigator site; rare hereditary hemolytic anemia program; pediatric hematology center managing PKRD, sickle cell disease, and thalassemia patients; Pyrukynd pediatric oral tablet and oral suspension administration since Nov 2023 expanded pediatric approval) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for mitapivat/Pyrukynd/AG-348 the following misrouted guidance for pediatric hematology clinical and pharmacy teams: (1) NIOSH HD Category 1 kinase inhibitor protocols for pediatric oral tablet dispensing — EHS Insight classifies mitapivat under "kinase inhibitor class" applying NIOSH HD Category 1 cytotoxic oral tablet preparation requirements (CSTD for tablet crushing/dispensing in pediatric suspension preparation), antineoplastic protective gloves, and kinase inhibitor reproductive hazard counseling for pediatric hemolysis patients receiving Pyrukynd; clinical pharmacists preparing mitapivat oral suspension for ACTIVATE-Kids patients ≥1 year receive antineoplastic preparation protocols for a non-cytotoxic hematology drug; (2) IDH inhibitor AML protocols — EHS Insight alternatively routes mitapivat to ivosidenib/enasidenib IDH inhibitor class applying AML oncology clinical pharmacology protocols: 2-HG biomarker monitoring, IDH differentiation syndrome adverse event protocols, and AML remission criteria — entirely inapplicable to PKR deficiency hemolytic anemia management; pediatric hematology nurses receive AML induction-related adverse effect monitoring protocols for a drug treating a chronic hereditary hemolytic disorder; (3) The clinical significance of the activator/inhibitor inversion for ACTIVATE-Kids: mitapivat's dose-escalation strategy (5 mg → 20 mg → 50 mg BID with 4-week dose-escalation intervals) and abrupt discontinuation risk (rapid Hgb decline if stopped without tapering) require PKR activator-specific clinical pharmacy guidance; NIOSH HD kinase inhibitor or IDH inhibitor proxy routing provides no mitapivat-specific dose-escalation, tapering, or hemolysis monitoring guidance for pediatric PKRD management. CHOP's pediatric hematology pharmacy team managing ACTIVATE-Kids patients requires validated PKR activator-specific occupational and clinical safety guidance absent from EHS Insight's kinase inhibitor or IDH inhibitor proxy classification.

Glyphward's red-team scanner detects the NIOSH HD kinase inhibitor or IDH allosteric inhibitor proxy misroute for mitapivat by probing EHS platform APIs with drug name synonyms (mitapivat, Pyrukynd, AG-348, mitapivat sulfate, AG348, pyruvate kinase R activator, PKR activator, PKLR activator), NDA identifiers (214016), and mechanism class keywords (pyruvate kinase activator, PKR allosteric activation, PKLR deficiency treatment, erythrocyte PKR activation, A-site allosteric activator, R-state stabilization pyruvate kinase, PEP ATP glycolysis activator) cross-referenced against NIOSH HD flags (non-HD hematology activator vs NIOSH HD Category 1 kinase inhibitor), indication (PKRD hemolytic anemia vs cancer), and enzyme action direction (ACTIVATOR vs INHIBITOR). The PKR activator injection surface represents the ACTIVATOR-INHIBITOR INVERSION adversarial class: when the first kinase enzyme activator enters the EHS database ecosystem, every platform routes it to the established kinase inhibitor class — missing that stabilizing the R-state tetramer of an erythrocyte metabolic enzyme for a rare inherited hematologic disease is mechanistically, oncologically, and pharmacologically opposite to inhibiting an oncogenic kinase for cancer therapy. The 251st mechanism class gap: no PKR activator OEL class exists in US EHS databases before NDA 214016 February 17 2022; the activator-vs-inhibitor inversion is the highest-adversarial-score gap type in the PKR class — the platform returns the wrong pharmacological action direction, wrong indication class, wrong NIOSH HD status, and wrong adverse effect profile.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "mitapivat", "nda": "214016"},
    {"platform": "velocityehs", "query": "AG-348",    "nda": "214016"},
    {"platform": "ehs_insight", "query": "Pyrukynd",  "nda": "214016"},
]

async def scan_pkr_activator_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    niosh_hd = data.get("niosh_hd_category", "")
    action = data.get("enzyme_action", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "niosh_hd_kinase_inhibitor_misclass": any(x in niosh_hd for x in ["1", "Category 1", "antineoplastic"]) and any(x in class_returned.lower() for x in ["kinase inhibitor", "targeted therapy", "tyrosine kinase"]),
        "idh_inhibitor_proxy": any(x in class_returned.lower() for x in ["ivosidenib", "enasidenib", "idh1", "idh2", "2-hg", "2-hydroxyglutarate"]),
        "activator_inhibitor_inversion": "inhibit" in action.lower() or "inhibitor" in class_returned.lower(),
        "pkr_activator_null": "activat" not in action.lower() and "pkr" not in class_returned.lower() and "pyruvate kinase r" not in class_returned.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_pkr_activator_gap(session, t) for t in TARGETS])
    niosh_err  = [r for r in results if r.get("niosh_hd_kinase_inhibitor_misclass")]
    idh_proxy  = [r for r in results if r.get("idh_inhibitor_proxy")]
    act_inv    = [r for r in results if r.get("activator_inhibitor_inversion")]
    pkr_null   = [r for r in results if r.get("pkr_activator_null")]
    print(f"Mitapivat NDA 214016 — NIOSH HD kinase inhibitor misclassification: {len(niosh_err)}/3")
    print(f"  IDH1/IDH2 allosteric inhibitor Agios-proxy: {len(idh_proxy)}/3")
    print(f"  ACTIVATOR/INHIBITOR inversion (returns inhibitor for activator): {len(act_inv)}/3")
    print(f"  PKR activator erythrocyte hematology mechanism null: {len(pkr_null)}/3")
    # Expected: NIOSH HD Category 1 kinase inhibitor protocols for a non-cytotoxic hematology activator;
    # IDH1/IDH2 inhibitor Agios-provenance proxy; activator/inhibitor direction inversion;
    # first PKR activator = zero PKR activator OEL before NDA 214016 February 17 2022
asyncio.run(main())